In a sector of constant innovation, a company must be something special if even the experts are excited. These are the four ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Pharmaceutical stock Gilead Sciences Inc (NASDAQ:GILD) is down 2.6% at $107.34, after news that domestic HIV prevention is ...

By Samantha [email protected] The Antigua Planned Parenthood Association (APPA) hosted a community health day at the Mack Pond football ...

Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' ...

Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...

We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.

A blood test to detect antiretroviral drugs showed that only 4% of those with viremia ... recruited 569 men living with HIV who had been traced from chart reviews at 13 health facilities. Men were ...

Josh Brown, CEO of Ritholtz Wealth Management, said during a program on CNBC last month that he’s paying attention to Gilead Sciences Inc (NASDAQ:GILD).

March is Human Rights Month, and last week, we commemorated this day in the Eastern Cape. As South Africans, we were reminded of where we come from, and the prize paid for our freedom. This day was ...

“The actual best chart in the S&P right now is Altria ... the FDA approved its new liver disease treatment for biliary ...

Following claims by the National Agency for Food and Drug Administration and Control that the Southeast region accounts for ...